Click here to get full coverage on MBRX Stock Price, Quote & Chart | MOLECULIN BIOTECH INC (NASDAQ:MBRX) - ChartMill

MBRX Stock Price, Quote & Chart | MOLECULIN BIOTECH INC (NASDAQ:MBRX)  ChartMill

MBRX Stock Price, Quote & Chart | MOLECULIN BIOTECH INC (NASDAQ:MBRX) - ChartMill

Click here to get full coverage on Annamycin cardiac safety data at ASCO 2026 for Moleculin (NASDAQ: MBRX) - Stock Titan

Annamycin cardiac safety data at ASCO 2026 for Moleculin (NASDAQ: MBRX)  Stock Titan

Annamycin cardiac safety data at ASCO 2026 for Moleculin (NASDAQ: MBRX) - Stock Titan

Click here to get full coverage on Why Did MBRX Stock Plummet Over 25% Today? - MSN

Why Did MBRX Stock Plummet Over 25% Today?  MSN

Why Did MBRX Stock Plummet Over 25% Today? - MSN

Click here to get full coverage on $MBRX stock is down 17% today. Here's what we see in our data. - Quiver Quantitative

$MBRX stock is down 17% today. Here's what we see in our data.  Quiver Quantitative

$MBRX stock is down 17% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on Moleculin Biotech 1Q Loss/Shr $3.54 >MBRX - Moomoo

Moleculin Biotech 1Q Loss/Shr $3.54 >MBRX  Moomoo

Moleculin Biotech 1Q Loss/Shr $3.54 >MBRX - Moomoo

Click here to get full coverage on MBRX: Annamycin advanced in pivotal AML trial; net loss widened, and more funding is needed for operations - TradingView

MBRX: Annamycin advanced in pivotal AML trial; net loss widened, and more funding is needed for operations  TradingView

MBRX: Annamycin advanced in pivotal AML trial; net loss widened, and more funding is needed for operations - TradingView

Click here to get full coverage on Pooled trials of cancer drug Annamycin find no cardiotoxicity signal - Stock Titan

Pooled trials of cancer drug Annamycin find no cardiotoxicity signal  Stock Titan

Pooled trials of cancer drug Annamycin find no cardiotoxicity signal - Stock Titan

Click here to get full coverage on Maxim Group Maintains Moleculin Biotech(MBRX.US) With Buy Rating, Maintains Target Price $10 - Moomoo

Maxim Group Maintains Moleculin Biotech(MBRX.US) With Buy Rating, Maintains Target Price $10  Moomoo

Maxim Group Maintains Moleculin Biotech(MBRX.US) With Buy Rating, Maintains Target Price $10 - Moomoo

Click here to get full coverage on Ahead of Phase 3 data, Moleculin adds Hong Kong patent for Annamycin - Stock Titan

Ahead of Phase 3 data, Moleculin adds Hong Kong patent for Annamycin  Stock Titan

Ahead of Phase 3 data, Moleculin adds Hong Kong patent for Annamycin - Stock Titan

Click here to get full coverage on Leukemia trial shows 40% remissions; first MIRACLE data unblinding due June 2026 - Stock Titan

Leukemia trial shows 40% remissions; first MIRACLE data unblinding due June 2026  Stock Titan

Leukemia trial shows 40% remissions; first MIRACLE data unblinding due June 2026 - Stock Titan

Click here to get full coverage on Leukemia study nears June data reveal after early 30% remission rate - Stock Titan

Leukemia study nears June data reveal after early 30% remission rate  Stock Titan

Leukemia study nears June data reveal after early 30% remission rate - Stock Titan

Click here to get full coverage on Moleculin (NASDAQ: MBRX) Q1 2026 loss deepens while MIRACLE AML trial progresses - Stock Titan

Moleculin (NASDAQ: MBRX) Q1 2026 loss deepens while MIRACLE AML trial progresses  Stock Titan

Moleculin (NASDAQ: MBRX) Q1 2026 loss deepens while MIRACLE AML trial progresses - Stock Titan

Click here to get full coverage on Moleculin’s $8.3M warrant deal: 2,122,652 shares now, 6,367,956 new warrants - Stock Titan

Moleculin’s $8.3M warrant deal: 2,122,652 shares now, 6,367,956 new warrants  Stock Titan

Moleculin’s $8.3M warrant deal: 2,122,652 shares now, 6,367,956 new warrants - Stock Titan

Click here to get full coverage on Cancer drug heart-safety data earns Moleculin an ASCO poster slot - Stock Titan

Cancer drug heart-safety data earns Moleculin an ASCO poster slot  Stock Titan

Cancer drug heart-safety data earns Moleculin an ASCO poster slot - Stock Titan

Click here to get full coverage on Moleculin Biotech (MBRX) widens Q1 loss and flags funding gap for MIRACLE trial - Stock Titan

Moleculin Biotech (MBRX) widens Q1 loss and flags funding gap for MIRACLE trial  Stock Titan

Moleculin Biotech (MBRX) widens Q1 loss and flags funding gap for MIRACLE trial - Stock Titan

Click here to get full coverage on Moleculin (NASDAQ: MBRX) posts higher blinded AML remission rates vs cytarabine - Stock Titan

Moleculin (NASDAQ: MBRX) posts higher blinded AML remission rates vs cytarabine  Stock Titan

Moleculin (NASDAQ: MBRX) posts higher blinded AML remission rates vs cytarabine - Stock Titan

Click here to get full coverage on Cardiac data support Moleculin (NASDAQ: MBRX) Annamycin use in R/R AML - Stock Titan

Cardiac data support Moleculin (NASDAQ: MBRX) Annamycin use in R/R AML  Stock Titan

Cardiac data support Moleculin (NASDAQ: MBRX) Annamycin use in R/R AML - Stock Titan

Click here to get full coverage on In pancreatic cancer models, Moleculin drug stretched survival to 29 days - Stock Titan

In pancreatic cancer models, Moleculin drug stretched survival to 29 days  Stock Titan

In pancreatic cancer models, Moleculin drug stretched survival to 29 days - Stock Titan

Click here to get full coverage on Moleculin's leukemia drug heads for a 45-patient readout in 2026 - Stock Titan

Moleculin's leukemia drug heads for a 45-patient readout in 2026  Stock Titan

Moleculin's leukemia drug heads for a 45-patient readout in 2026 - Stock Titan

Click here to get full coverage on AML chemo exceeds heart-dose limits with no signs of damage - Stock Titan

AML chemo exceeds heart-dose limits with no signs of damage  Stock Titan

AML chemo exceeds heart-dose limits with no signs of damage - Stock Titan

Click here to get full coverage on Experimental chemo aiming to spare the heart nears key 2026 trial test - Stock Titan

Experimental chemo aiming to spare the heart nears key 2026 trial test  Stock Titan

Experimental chemo aiming to spare the heart nears key 2026 trial test - Stock Titan

Click here to get full coverage on New Moleculin (NASDAQ: MBRX) patent bolsters Annamycin IP before Phase 3 data - Stock Titan

New Moleculin (NASDAQ: MBRX) patent bolsters Annamycin IP before Phase 3 data  Stock Titan

New Moleculin (NASDAQ: MBRX) patent bolsters Annamycin IP before Phase 3 data - Stock Titan

Click here to get full coverage on Moleculin Biotech Shares Slide After Announcing 1-for-25 Reverse Split - MSN

Moleculin Biotech Shares Slide After Announcing 1-for-25 Reverse Split  MSN

Moleculin Biotech Shares Slide After Announcing 1-for-25 Reverse Split - MSN

Click here to get full coverage on MBRX: Pivotal AML trial hits key enrollment, 40% remission rate; Q1 net loss $12.8M, cash runway into Q3 - TradingView

MBRX: Pivotal AML trial hits key enrollment, 40% remission rate; Q1 net loss $12.8M, cash runway into Q3  TradingView

MBRX: Pivotal AML trial hits key enrollment, 40% remission rate; Q1 net loss $12.8M, cash runway into Q3 - TradingView

Click here to get full coverage on MBRX Q1'26 Earnings: EPS estimate is (1.66) USD - TradingView

MBRX Q1'26 Earnings: EPS estimate is (1.66) USD  TradingView

MBRX Q1'26 Earnings: EPS estimate is (1.66) USD - TradingView

Click here to get full coverage on Moleculin Highlights Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting Highlighting Cardiac Safety Data for Annamycin - Sahm

Moleculin Highlights Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting Highlighting Cardiac Safety Data for Annamycin  Sahm

Moleculin Highlights Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting Highlighting Cardiac Safety Data for Annamycin - Sahm

Click here to get full coverage on Moleculin Biotech, Inc. Announces 1-for-25 Reverse Stock Split Effective December 1, 2025 - Quiver Quantitative

Moleculin Biotech, Inc. Announces 1-for-25 Reverse Stock Split Effective December 1, 2025  Quiver Quantitative

Moleculin Biotech, Inc. Announces 1-for-25 Reverse Stock Split Effective December 1, 2025 - Quiver Quantitative

Click here to get full coverage on [EFFECT] Moleculin Biotech, Inc. SEC Filing - Stock Titan

[EFFECT] Moleculin Biotech, Inc. SEC Filing  Stock Titan

[EFFECT] Moleculin Biotech, Inc. SEC Filing - Stock Titan

Click here to get full coverage on New Moleculin CEO Corner invites investor questions on trials, strategy - Stock Titan

New Moleculin CEO Corner invites investor questions on trials, strategy  Stock Titan

New Moleculin CEO Corner invites investor questions on trials, strategy - Stock Titan

Click here to get full coverage on Moleculin Announces Exercise of Warrants for $6.8 Million Gross Proceeds - Yahoo Finance

Moleculin Announces Exercise of Warrants for $6.8 Million Gross Proceeds  Yahoo Finance

Moleculin Announces Exercise of Warrants for $6.8 Million Gross Proceeds - Yahoo Finance

Click here to get full coverage on Why Did MBRX Stock Climb 14% Today? - Stocktwits

Why Did MBRX Stock Climb 14% Today?  Stocktwits

Why Did MBRX Stock Climb 14% Today? - Stocktwits

Click here to get full coverage on Moleculin (NASDAQ: MBRX) hits 45-subject milestone in pivotal MIRACLE AML trial - Stock Titan

Moleculin (NASDAQ: MBRX) hits 45-subject milestone in pivotal MIRACLE AML trial  Stock Titan

Moleculin (NASDAQ: MBRX) hits 45-subject milestone in pivotal MIRACLE AML trial - Stock Titan

Click here to get full coverage on Nano-Cap Moleculin Biotech Approaches Key Leukemia Trial Data Unblinding - Yahoo Finance

Nano-Cap Moleculin Biotech Approaches Key Leukemia Trial Data Unblinding  Yahoo Finance

Nano-Cap Moleculin Biotech Approaches Key Leukemia Trial Data Unblinding - Yahoo Finance

Click here to get full coverage on MBRX: HC Wainwright & Co. Reiterates Buy Rating and Price Target - GuruFocus

MBRX: HC Wainwright & Co. Reiterates Buy Rating and Price Target  GuruFocus

MBRX: HC Wainwright & Co. Reiterates Buy Rating and Price Target - GuruFocus

Click here to get full coverage on MBRX Stock Reverse Split 2025 Amid Biotech Bankruptcies: Analysts Remain Bullish - bitget.com

MBRX Stock Reverse Split 2025 Amid Biotech Bankruptcies: Analysts Remain Bullish  bitget.com

MBRX Stock Reverse Split 2025 Amid Biotech Bankruptcies: Analysts Remain Bullish - bitget.com

Click here to get full coverage on Moleculin Biotech Inc. (MBRX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade

Moleculin Biotech Inc. (MBRX) Stock Price | Live Quotes & Charts | NASDAQ  StocksToTrade

Moleculin Biotech Inc. (MBRX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade

Click here to get full coverage on Maxim Group Maintains Moleculin Biotech(MBRX.US) With Buy Rating, Maintains Target Price $10 - 富途牛牛

Maxim Group Maintains Moleculin Biotech(MBRX.US) With Buy Rating, Maintains Target Price $10  富途牛牛

Maxim Group Maintains Moleculin Biotech(MBRX.US) With Buy Rating, Maintains Target Price $10 - 富途牛牛

Click here to get full coverage on Why Did MBRX Stock Plummet Over 25% Today? - Stocktwits

Why Did MBRX Stock Plummet Over 25% Today?  Stocktwits

Why Did MBRX Stock Plummet Over 25% Today? - Stocktwits

Click here to get full coverage on Moleculin Biotech (MBRX) Sees Significant Price Target Upgrade - GuruFocus

Moleculin Biotech (MBRX) Sees Significant Price Target Upgrade  GuruFocus

Moleculin Biotech (MBRX) Sees Significant Price Target Upgrade - GuruFocus

Click here to get full coverage on Moleculin Announces Reverse Stock Split - GlobeNewswire

Moleculin Announces Reverse Stock Split  GlobeNewswire

Moleculin Announces Reverse Stock Split - GlobeNewswire

Click here to get full coverage on Moleculin Biotech Secures Hong Kong Patent for Annamycin Method Ahead of Phase 3 Clinical Data Release - Quiver Quantitative

Moleculin Biotech Secures Hong Kong Patent for Annamycin Method Ahead of Phase 3 Clinical Data Release  Quiver Quantitative

Moleculin Biotech Secures Hong Kong Patent for Annamycin Method Ahead of Phase 3 Clinical Data Release - Quiver Quantitative

Click here to get full coverage on Moleculin Biotech Reports Promising Early Results in MIRACLE Trial for AML Treatment with 40% Composite Complete Remission Rate - Quiver Quantitative

Moleculin Biotech Reports Promising Early Results in MIRACLE Trial for AML Treatment with 40% Composite Complete Remission Rate  Quiver Quantitative

Moleculin Biotech Reports Promising Early Results in MIRACLE Trial for AML Treatment with 40% Composite Complete Remission Rate - Quiver Quantitative

Click here to get full coverage on Moleculin Approaching First MIRACLE Trial Unblinding; Preliminary CR ~30% vs 17–18% SOC - TradingView

Moleculin Approaching First MIRACLE Trial Unblinding; Preliminary CR ~30% vs 17–18% SOC  TradingView

Moleculin Approaching First MIRACLE Trial Unblinding; Preliminary CR ~30% vs 17–18% SOC - TradingView

Click here to get full coverage on Moleculin Biotech stock plunges after warrant exercise agreement - Investing.com

Moleculin Biotech stock plunges after warrant exercise agreement  Investing.com

Moleculin Biotech stock plunges after warrant exercise agreement - Investing.com

Click here to get full coverage on Moleculin Biotech (MBRX) Nears Key Milestone in Leukemia Trial P - GuruFocus

Moleculin Biotech (MBRX) Nears Key Milestone in Leukemia Trial P  GuruFocus

Moleculin Biotech (MBRX) Nears Key Milestone in Leukemia Trial P - GuruFocus

Click here to get full coverage on Moleculin Biotech stock drops after announcing 1-for-25 reverse split - Investing.com

Moleculin Biotech stock drops after announcing 1-for-25 reverse split  Investing.com

Moleculin Biotech stock drops after announcing 1-for-25 reverse split - Investing.com

Click here to get full coverage on Moleculin Releases Next CEO Corner Segment Highlighting MIRACLE Study - Yahoo Finance

Moleculin Releases Next CEO Corner Segment Highlighting MIRACLE Study  Yahoo Finance

Moleculin Releases Next CEO Corner Segment Highlighting MIRACLE Study - Yahoo Finance

Click here to get full coverage on Moleculin MIRACLE Trial Delivers 40% Preliminary Blinded CRc Rate (n=30) - GlobeNewswire

Moleculin MIRACLE Trial Delivers 40% Preliminary Blinded CRc Rate (n=30)  GlobeNewswire

Moleculin MIRACLE Trial Delivers 40% Preliminary Blinded CRc Rate (n=30) - GlobeNewswire

Click here to get full coverage on Moleculin Biotech Inc - To Unblind Miracle Trial Data Before June 30, 2026 - SEC Filing - TradingView

Moleculin Biotech Inc - To Unblind Miracle Trial Data Before June 30, 2026 - SEC Filing  TradingView

Moleculin Biotech Inc - To Unblind Miracle Trial Data Before June 30, 2026 - SEC Filing - TradingView

Click here to get full coverage on Moleculin Biotech Inc reports results for the quarter ended March 31 - Earnings Summary - TradingView

Moleculin Biotech Inc reports results for the quarter ended March 31 - Earnings Summary  TradingView

Moleculin Biotech Inc reports results for the quarter ended March 31 - Earnings Summary - TradingView

Click here to get full coverage on Moleculin Biotech 10-K: No Revenue, Net Loss $33.6M, Ops Loss $25.1M - TradingView

Moleculin Biotech 10-K: No Revenue, Net Loss $33.6M, Ops Loss $25.1M  TradingView

Moleculin Biotech 10-K: No Revenue, Net Loss $33.6M, Ops Loss $25.1M - TradingView

Click here to get full coverage on Moleculin to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial - Yahoo Finance

Moleculin to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial  Yahoo Finance

Moleculin to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial - Yahoo Finance

Click here to get full coverage on Moleculin Biotech receives Nasdaq delisting notice, plans to appeal - Investing.com

Moleculin Biotech receives Nasdaq delisting notice, plans to appeal  Investing.com

Moleculin Biotech receives Nasdaq delisting notice, plans to appeal - Investing.com

Click here to get full coverage on Moleculin Biotech stockholders approve warrant issuance, reject name change - Investing.com

Moleculin Biotech stockholders approve warrant issuance, reject name change  Investing.com

Moleculin Biotech stockholders approve warrant issuance, reject name change - Investing.com

Click here to get full coverage on Moleculin Biotech’s Bold Move: Stock Split Announced - StocksToTrade

Moleculin Biotech’s Bold Move: Stock Split Announced  StocksToTrade

Moleculin Biotech’s Bold Move: Stock Split Announced - StocksToTrade

Click here to get full coverage on Moleculin Announces Notice of Allowance for Japanese Patent Covering Annamycin - Yahoo Finance

Moleculin Announces Notice of Allowance for Japanese Patent Covering Annamycin  Yahoo Finance

Moleculin Announces Notice of Allowance for Japanese Patent Covering Annamycin - Yahoo Finance

Click here to get full coverage on Moleculin Reports First Quarter 2026 Financial Results and Provides Clinical Update on Pivotal MIRACLE Trial - GlobeNewswire

Moleculin Reports First Quarter 2026 Financial Results and Provides Clinical Update on Pivotal MIRACLE Trial  GlobeNewswire

Moleculin Reports First Quarter 2026 Financial Results and Provides Clinical Update on Pivotal MIRACLE Trial - GlobeNewswire

Click here to get full coverage on MBRX Technical Analysis & ETF Price Forecast - Intellectia AI

MBRX Technical Analysis & ETF Price Forecast  Intellectia AI

MBRX Technical Analysis & ETF Price Forecast - Intellectia AI

Click here to get full coverage on Moleculin Hits 45 Subject Enrollment Milestone, Triggering Final Countdown to Mid-2026 MIRACLE Trial Data Readout - Yahoo Finance

Moleculin Hits 45 Subject Enrollment Milestone, Triggering Final Countdown to Mid-2026 MIRACLE Trial Data Readout  Yahoo Finance

Moleculin Hits 45 Subject Enrollment Milestone, Triggering Final Countdown to Mid-2026 MIRACLE Trial Data Readout - Yahoo Finance

Click here to get full coverage on Moleculin Biotech stock falls after warrant exercise agreement - Investing.com

Moleculin Biotech stock falls after warrant exercise agreement  Investing.com

Moleculin Biotech stock falls after warrant exercise agreement - Investing.com

Click here to get full coverage on Moleculin Biotech Secures Strategic Additional Patent, Strengthening Global Positioning of Annamycin - GlobeNewswire

Moleculin Biotech Secures Strategic Additional Patent, Strengthening Global Positioning of Annamycin  GlobeNewswire

Moleculin Biotech Secures Strategic Additional Patent, Strengthening Global Positioning of Annamycin - GlobeNewswire

Click here to get full coverage on Moleculin Biotech releases CEO update on leukemia trial - Investing.com

Moleculin Biotech releases CEO update on leukemia trial  Investing.com

Moleculin Biotech releases CEO update on leukemia trial - Investing.com

Click here to get full coverage on Moleculin Announces Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting - GlobeNewswire

Moleculin Announces Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting  GlobeNewswire

Moleculin Announces Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting - GlobeNewswire

Click here to get full coverage on Moleculin Biotech stockholders approve warrant issuance, decline name change - Investing.com

Moleculin Biotech stockholders approve warrant issuance, decline name change  Investing.com

Moleculin Biotech stockholders approve warrant issuance, decline name change - Investing.com

Click here to get full coverage on Moleculin Biotech Appeals Nasdaq Delisting Decision - The Globe and Mail

Moleculin Biotech Appeals Nasdaq Delisting Decision  The Globe and Mail

Moleculin Biotech Appeals Nasdaq Delisting Decision - The Globe and Mail

Click here to get full coverage on Moleculin Biotech Bets Big On New Cancer Drug Trials - Finimize

Moleculin Biotech Bets Big On New Cancer Drug Trials  Finimize

Moleculin Biotech Bets Big On New Cancer Drug Trials - Finimize

Click here to get full coverage on Moleculin Announces Imminent MIRACLE Trial Unblinding as - GlobeNewswire

Moleculin Announces Imminent MIRACLE Trial Unblinding as  GlobeNewswire

MBRX

Price Chart

Key Statistics

Technicals

About MBRX

Latest News

MBRX Stock Price, Quote & Chart | MOLECULIN BIOTECH INC (NASDAQ:MBRX) - ChartMill

Annamycin cardiac safety data at ASCO 2026 for Moleculin (NASDAQ: MBRX) - Stock Titan

Why Did MBRX Stock Plummet Over 25% Today? - MSN

Advanced Charts

Top Gainers

Top Losers